828 related articles for article (PubMed ID: 24580837)
21. Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines.
Boegsted M; Holst JM; Fogd K; Falgreen S; Sørensen S; Schmitz A; Bukh A; Johnsen HE; Nyegaard M; Dybkaer K
PLoS One; 2011 Apr; 6(4):e19322. PubMed ID: 21559449
[TBL] [Abstract][Full Text] [Related]
22. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
[TBL] [Abstract][Full Text] [Related]
23. Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles.
Visser S; Hou J; Bezemer K; de Vogel LL; Hegmans JPJJ; Stricker BH; Philipsen S; Aerts JGJV
BMC Cancer; 2019 May; 19(1):440. PubMed ID: 31088547
[TBL] [Abstract][Full Text] [Related]
24. Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer.
Wu X; Li Y; Wang J; Wen X; Marcus MT; Daniels G; Zhang DY; Ye F; Wang LH; Du X; Adams S; Singh B; Zavadil J; Lee P; Monaco ME
PLoS One; 2013; 8(10):e77060. PubMed ID: 24155918
[TBL] [Abstract][Full Text] [Related]
25. Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma.
Laursen MB; Falgreen S; Bødker JS; Schmitz A; Kjeldsen MK; Sørensen S; Madsen J; El-Galaly TC; Bøgsted M; Dybkær K; Johnsen HE;
Exp Hematol; 2014 Nov; 42(11):927-38. PubMed ID: 25072621
[TBL] [Abstract][Full Text] [Related]
26. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.
O'Brien C; Cavet G; Pandita A; Hu X; Haydu L; Mohan S; Toy K; Rivers CS; Modrusan Z; Amler LC; Lackner MR
Cancer Res; 2008 Jul; 68(13):5380-9. PubMed ID: 18593940
[TBL] [Abstract][Full Text] [Related]
27. Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines.
O'Neill F; Madden SF; Aherne ST; Clynes M; Crown J; Doolan P; O'Connor R
Mol Cancer; 2012 Jun; 11():41. PubMed ID: 22709873
[TBL] [Abstract][Full Text] [Related]
28. microRNA and Lung Cancer.
Del Vescovo V; Denti MA
Adv Exp Med Biol; 2015; 889():153-77. PubMed ID: 26659001
[TBL] [Abstract][Full Text] [Related]
29. A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions.
Mian S; Ball G; Hornbuckle J; Holding F; Carmichael J; Ellis I; Ali S; Li G; McArdle S; Creaser C; Rees R
Proteomics; 2003 Sep; 3(9):1725-37. PubMed ID: 12973733
[TBL] [Abstract][Full Text] [Related]
30. Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib.
Hickinson DM; Marshall GB; Beran GJ; Varella-Garcia M; Mills EA; South MC; Cassidy AM; Acheson KL; McWalter G; McCormack RM; Bunn PA; French T; Graham A; Holloway BR; Hirsch FR; Speake G
Clin Transl Sci; 2009 Jun; 2(3):183-92. PubMed ID: 20443891
[TBL] [Abstract][Full Text] [Related]
31. A transfer learning approach via procrustes analysis and mean shift for cancer drug sensitivity prediction.
Turki T; Wei Z; Wang JTL
J Bioinform Comput Biol; 2018 Jun; 16(3):1840014. PubMed ID: 29945499
[TBL] [Abstract][Full Text] [Related]
32. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
[TBL] [Abstract][Full Text] [Related]
33. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.
Tahir SK; Wass J; Joseph MK; Devanarayan V; Hessler P; Zhang H; Elmore SW; Kroeger PE; Tse C; Rosenberg SH; Anderson MG
Mol Cancer Ther; 2010 Mar; 9(3):545-57. PubMed ID: 20179162
[TBL] [Abstract][Full Text] [Related]
34. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
35. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive expression-based isoform biomarkers predictive of drug responses based on isoform co-expression networks and clinical data.
Ma J; Wang J; Ghoraie LS; Men X; Chen R; Dai P
Genomics; 2020 Jan; 112(1):647-658. PubMed ID: 31029864
[TBL] [Abstract][Full Text] [Related]
38. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Ross DD; Yang W; Abruzzo LV; Dalton WS; Schneider E; Lage H; Dietel M; Greenberger L; Cole SP; Doyle LA
J Natl Cancer Inst; 1999 Mar; 91(5):429-33. PubMed ID: 10070941
[TBL] [Abstract][Full Text] [Related]
39. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
Zhou W; Wang J; Man WY; Zhang QW; Xu WG
Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Shaughnessy JD; Qu P; Usmani S; Heuck CJ; Zhang Q; Zhou Y; Tian E; Hanamura I; van Rhee F; Anaissie E; Epstein J; Nair B; Stephens O; Williams R; Waheed S; Alsayed Y; Crowley J; Barlogie B
Blood; 2011 Sep; 118(13):3512-24. PubMed ID: 21628408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]